Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 5,500 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 5,500 shares of the business’s stock in a transaction dated Friday, April 4th. The stock was purchased at an average price of $8.73 per share, for a total transaction of $48,015.00. Following the completion of the acquisition, the chief executive officer now owns 5,558,002 shares in the company, valued at approximately $48,521,357.46. This trade represents a 0.10 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Friday, January 10th, Snehal Patel bought 2,500 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $12.51 per share, with a total value of $31,275.00.
• On Tuesday, January 7th, Snehal Patel acquired 1,800 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $13.75 per share, with a total value of $24,750.00.

Greenwich LifeSciences Price Performance

Shares of NASDAQ GLSI opened at $9.59 on Tuesday. Greenwich LifeSciences, Inc. has a 1-year low of $8.06 and a 1-year high of $18.75. The company has a market capitalization of $126.06 million, a price-to-earnings ratio of -11.99 and a beta of 1.76. The business has a 50-day moving average of $11.65 and a 200-day moving average of $12.75.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of Greenwich LifeSciences in a report on Tuesday, February 11th.

Hedge Funds Weigh In On Greenwich LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Garden State Investment Advisory Services LLC acquired a new stake in Greenwich LifeSciences in the third quarter valued at approximately $253,000. Northern Trust Corp boosted its stake in shares of Greenwich LifeSciences by 17.3% in the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock valued at $982,000 after purchasing an additional 12,923 shares during the period. Barclays PLC grew its holdings in Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after purchasing an additional 6,538 shares in the last quarter. Geode Capital Management LLC increased its stake in Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Greenwich LifeSciences by 172.0% in the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after buying an additional 4,465 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.